Étiquette : psychose

Priority Considerations for Medicinal Cannabis-Related Research, Marcel O. Bonn-Miller et al.,

Priority Considerations for Medicinal Cannabis-Related Research Marcel O. Bonn-Miller, Charles V. Pollack, Jr., David Casarett, Richard Dart, Mahmoud ElSohly, Larry Good, Manuel Guzman, Lumır Hanus, Kevin P. Hill, Marilyn A. Huestis, Eric Marsh, Susan Sisley, Nancy Skinner, Judith Spahr, Ryan Vandrey, Eugene Viscusi, Mark A. Ware, and Donald Abrams Cannabis and Cannabinoid Research, 2019, Volume 4, Number 3, 1-19. DOI: 10.1089/can.2019.0045   Keywords : medicinal cannabis; medical marijuana   Introduction and Rationale The National Academy of Sciences, Engineering, and Medicine’s 2017 publication The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research provided a significant contribution by synthesizing the existing evidence base [...]

Lire la suite

The Relevance of Sex in the Association of Synthetic Cannabinoid Use With Psychosis and Agitation in an Inpatient Population, Anahita Bassir Nia et al., 2019

The Relevance of Sex in the Association of Synthetic Cannabinoid Use With Psychosis and Agitation in an Inpatient Population Anahita Bassir Nia, MD‡; Claire L. Mann, BA; Sharron Spriggs, MA; Daniel R. DeFrancisco, MD; Steven Carbonaro, MD; Lyla Parvez, MA; Igor I. Galynker, MD, PhD; Charles A. Perkel, MD; and Yasmin L. Hurd, PhD Journal of Clinical Psychiatry, 2019, 80, (4), 18m12539 https://doi.org/10.4088/JCP.18m12539 Background : Current evidence suggests that women are more sensitive to the effects of cannabinoids. The aim of this study was to investigate the relevance of sex in the association of synthetic cannabinoid (SC) use with psychosis and agitation. Methods : A [...]

Lire la suite

Endocannabinoid signaling in psychiatric disorders: a review of positron emission tomography studies, Matthew E. Sloan et al., 2018

Endocannabinoid signaling in psychiatric disorders: a review of positron emission tomography studies Matthew E. Sloan, Caroline W. Grant, Joshua L. Gowin, Vijay A. Ramchandani and Bernard Le Foll Acta Pharmacologica Sinica, 2018, 0, 1–9; https://doi.org/10.1038/s41401-018-0081-z   Endocannabinoid signaling is implicated in an array of psychopathologies ranging from anxiety to psychosis and addiction. In recent years, radiotracers targeting the endocannabinoid system have been used in positron emission tomography (PET) studies to determine whether individuals with psychiatric disorders display altered endocannabinoid signaling. We comprehensively reviewed PET studies examining differences in endocannabinoid signaling between individuals with psychiatric illness and healthy controls. Published studies evaluated individuals with five psychiatric [...]

Lire la suite

Case Series: Salvia divinorum as a Potential Addictive Hallucinogen, Joseph El-Khoury & Evelyne Baroud, 2018

Case Series: Salvia divinorum as a Potential Addictive Hallucinogen Joseph El-Khoury, Evelyne Baroud The American Journal on Addictions, 2018, 27, 163–165 DOI: 10.1111/ajad.12715   Background and Objective : Recreational use of Salvia divinorum (salvia), a potent, naturally occurring hallucinogen, is on the rise internationally. Despite the paucity of information about its long term health effects, salvia is readily available and generally portrayed as a safe non-addictive substance. Methods and Results : We report on two patients who presented with an enduring and pervasive pattern of salvia use. Discussion and Conclusions : Evaluating patients for salvia use during clinical assessment is strongly encouraged, especially among young polysubstance users. Scientific [...]

Lire la suite

The Potential of Cannabidiol as a Treatment for Psychosis and Addiction : Who Benefits Most ? A Systematic Review, Albert Batalla et al., 2019

The Potential of Cannabidiol as a Treatment for Psychosis and Addiction : Who Benefits Most ? A Systematic Review Albert Batalla, Hella Janssen, Shiral S. Gangadin and Matthijs G. Bossong Journal of Clinical Medicine, 2019, 8, 1058 doi : 10.3390/jcm8071058 Abstract : The endogenous cannabinoid (eCB) system plays an important role in the pathophysiology of both psychotic disorders and substance use disorders (SUDs). The non-psychoactive cannabinoid compound, cannabidiol (CBD) is a highly promising tool in the treatment of both disorders. Here we review human clinical studies that investigated the ecacy of CBD treatment for schizophrenia, substance use disorders, and their comorbidity. In particular, we examined [...]

Lire la suite

Expanding the Scientific Study of Self-Experience with Psychedelics, Manesh Girn and Kalina Christoff, 2018

Expanding the Scientific Study of Self-Experience with Psychedelics Manesh Girn and Kalina Christoff Journal of Consciousness Studies, 2018, 25, (11–12), 131–54 Abstract : The nature of the self has long been a topic of discussion in philosophical and religious contexts, and has recently also garnered significant scientific attention. Although evidence exists to suggest the multifaceted nature of self-experience, the amount of research done on each of its putative components has not been uniform. Whereas selfreflective processing has been studied extensively, non-reflective aspects of self-experience have been the subject of comparatively little empirical research. This discrepancy may be linked to the methodological difficulties in experimentally [...]

Lire la suite

Reefer Madness : A Case of Cannabis-Induced Psychosis, Matthew C. Ballenberger et al., 2019

Reefer Madness : A Case of Cannabis-Induced Psychosis Matthew C. Ballenberger,  Robert D. Glatter,  Daniel P. Klein,  Steven Mandel, Medscape Psychiatry,  August 15, 2019 Clinical Presentation A 32-year-old woman with a history of iron-deficiency anemia was brought in by ambulance because of altered mental status. The patient's sister and boyfriend reported that 1 day before presentation, the patient had ingested a marijuana edible and a few hours later developed fatigue and nausea, followed by at least 15 episodes of nonbloody, nonbilious, projectile vomiting throughout the night. In the morning, she became very pale, her lips turned blue, and she became stiff, losing consciousness for [...]

Lire la suite

Model Psychoses Induced by LSD-25 in Normals. I. Psychophysiological Investigations, with Special Reference to the Mechanism of the Paranoid Reaction, Nicolas A. Bercelet al., 1956

Model Psychoses Induced by LSD-25 in Normals. I. Psychophysiological Investigations, with Special Reference to the Mechanism of the Paranoid Reaction Nicolas A. Bercel, Lee E. Travis, Leonard B. Olinger & E. Dreikurs AMA Archives of Neurology and Psychiatry, 1956, 588-611 republishing :Psychopathology: A Source Book (pp. 605–639). DOI: https://doi.org/10.4159/harvard.9780674367012 Keywords : Cardiovascular Agents, Ergot Alkaloids, adverse effects, Lysergic Acid Diethylamide, Mental Disorders, Oxytocics, Paranoid Disorders, Psychotic Disorders INTRODUCTION Experimental psychosis has a long history. It might have started with the administration of Cannabis indica boiling in wine to the ancient Hun warriors, resulting in mental obfuscation, as they were prepared for surgery because of wounds sustained in battle. [...]

Lire la suite

Psychopathology and Psychophysiology of Minimal LSD-25 Dosage. A Preliminary Dosage-Response Spectrum, Theodore GREINER et al., 1958

Psychopathology and Psychophysiology of Minimal LSD-25 Dosage. A Preliminary Dosage-Response Spectrum Theodore GREINER, Neil R. BURCH, Robert  EDELBERG AMA, Archives of  Neurology & Psychiatry, 1958, 79, (2), 208-210. doi:10.1001/archneurpsyc.1958.02340020088016 Abstract Despite 14 years of investigation, as intensive as accorded any biologically active chemical, a gap remains in the systematic description of human response to lysergic acid diethylamide (LSD-25). The dramatic schizophrenic-like symptoms after doses of 40 μg to 100 μg have drawn the main interest. The threshold for activity is placed at 20 μg by general consensus, while perfunctory administration of smaller doses has left their effect uncertain. Accompanying those pharmacologic demonstrations has been [...]

Lire la suite

Hallucinogen-persisting perception disorder, Leo Hermle et al., 2012

Hallucinogen-persisting perception disorder Leo Hermle, Melanie Simon, Martin Ruchsow and Martin Geppert Therapeutic Advances in Psychopharmacology, 2012, 2, (5), 199–205 DOI: 10.1177/2045125312451270   Abstract : A 33-year-old female patient developed a hallucinogen-persisting perception disorder (HPPD) after lysergic acid diethylamide (LSD) abuse for a year at the age of 18. Specifically, she reported after images, perception of movement in her peripheral visual fields, blurring of small patterns, halo effects, and macro- and micropsia. Previous treatment with antidepressants and risperidone failed to ameliorate these symptoms. Upon commencing drug therapy with lamotrigine, these complex visual disturbances receded almost completely. Based on its hypothesized neuroprotective and mood-stabilizing effects, the antiepileptic [...]

Lire la suite